$ENZ
ENZO BIOCHEM INC Stock $enz

$enz Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022079139 Filed on December 12, 2022

Income Statement

Concept	2022 Q4	2021 Q4
Revenue	$18.28M	$26.52M
YoY Change	-31.08%	-7.47%
Cost Of Revenue	$14.67M	$15.27M
YoY Change	-3.94%	-8.87%
Gross Profit	$3.605M	$11.25M
YoY Change	-67.94%	-5.5%
Gross Profit Margin	19.73%	42.41%
Selling, General & Admin	$11.45M	$11.05M
YoY Change	3.61%	10.41%
% of Gross Profit	317.64%	98.27%
Research & Development	$996.0K	$744.0K
YoY Change	33.87%	-0.8%
% of Gross Profit	27.63%	6.62%
Depreciation & Amortization	$780.0K	$701.0K
YoY Change	11.27%	4.63%
% of Gross Profit	21.64%	6.23%
Operating Expenses	$9.000K	$11.80M
YoY Change	-99.92%	9.63%
Operating Profit	-$9.913M	-$550.0K
YoY Change	1702.36%	-148.25%
Interest Expense	-$727.0K	-$342.0K
YoY Change	112.57%	55.45%
% of Operating Profit
Other Income/Expense, Net	$5.000K	-$145.0K
YoY Change	-103.45%	-825.0%
Pretax Income	-$10.64M	-$2.319M
YoY Change	358.6%	-873.0%
Income Tax
% Of Pretax Income
Net Earnings	-$10.64M	-$2.319M
YoY Change	358.6%	-873.0%
Net Earnings / Revenue	-58.19%	-8.74%
Basic Earnings Per Share	-$0.22	-$0.05
Diluted Earnings Per Share	-$0.22	-$47.84K
COMMON SHARES
Basic Shares Outstanding	48.72M shares	48.47K shares
Diluted Shares Outstanding	48.72K shares	48.47K shares

Balance Sheet

Concept	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.14M	$36.17M
YoY Change	-66.45%	-21.21%
Cash & Equivalents	$12.14M	$6.356M
Short-Term Investments		$29.81M
Other Short-Term Assets	$5.142M	$4.457M
YoY Change	15.37%	6.12%
Inventory	$15.79M	$13.96M
Prepaid Expenses	$5.142M
Receivables	$11.52M	$11.33M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$44.58M	$65.91M
YoY Change	-32.37%	-6.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.14M	$33.21M
YoY Change	-48.39%	-1.74%
Goodwill	$7.452M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.609M	$1.392M
YoY Change	15.59%	-7.2%
Total Long-Term Assets	$40.62M	$42.23M
YoY Change	-3.81%	-2.25%
TOTAL ASSETS
Total Short-Term Assets	$44.58M	$65.91M
Total Long-Term Assets	$40.62M	$42.23M
Total Assets	$85.20M	$108.1M
YoY Change	-21.21%	-4.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.109M	$5.929M
YoY Change	36.77%	-23.99%
Accrued Expenses	$12.38M	$14.84M
YoY Change	-16.61%	-7.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$228.0K	$235.0K
YoY Change	-2.98%	135.0%
Total Short-Term Liabilities	$24.25M	$23.11M
YoY Change	4.96%	-31.23%
LONG-TERM LIABILITIES
Long-Term Debt	$3.986M	$4.405M
YoY Change	-9.51%	-4.24%
Other Long-Term Liabilities	$18.00K	$13.87M
YoY Change	-99.87%	-14.92%
Total Long-Term Liabilities	$4.004M	$18.27M
YoY Change	-78.09%	-12.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.25M	$23.11M
Total Long-Term Liabilities	$4.004M	$18.27M
Total Liabilities	$40.21M	$41.38M
YoY Change	-2.83%	-24.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.3M
YoY Change
Common Stock	$487.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.99M	$66.76M
YoY Change
Total Liabilities & Shareholders Equity	$85.20M	$108.1M
YoY Change	-21.21%	-4.72%

Cashflow Statement

Concept	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$10.64M	-$2.319M
YoY Change	358.6%	-873.0%
Depreciation, Depletion And Amortization	$780.0K	$701.0K
YoY Change	11.27%	4.63%
Cash From Operating Activities	-$8.693M	-$6.043M
YoY Change	43.85%	399.42%
INVESTING ACTIVITIES
Capital Expenditures	-$652.0K	-$1.033M
YoY Change	-36.88%	66.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$28.00K
YoY Change	-100.0%
Cash From Investing Activities	-$652.0K	-$1.061M
YoY Change	-38.55%	71.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$95.00K	-57.00K
YoY Change	66.67%	-48.18%
NET CHANGE
Cash From Operating Activities	-$8.693M	-6.043M
Cash From Investing Activities	-$652.0K	-1.061M
Cash From Financing Activities	-$95.00K	-57.00K
Net Change In Cash	-$9.468M	-7.161M
YoY Change	32.22%	269.12%
FREE CASH FLOW
Cash From Operating Activities	-$8.693M	-$6.043M
Capital Expenditures	-$652.0K	-$1.033M
Free Cash Flow	-$8.041M	-$5.010M
YoY Change	60.5%	749.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	4000	usd
CY2022Q4	enz	Contractual Obligation Undiscounted Excess Amount ContractualObligationUndiscountedExcessAmount	1796000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-10-31
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	001-09974
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	ENZO BIOCHEM, INC.
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
CY2022Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-2866202
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	81 Executive Blvd
CY2022Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3 Farmingdale
CY2022Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11735
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	dei	Security12b Title Security12bTitle	Common stock $0.01 par
CY2022Q4	dei	Trading Symbol TradingSymbol	ENZ
CY2022Q4	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48720454	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12135000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21603000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11515000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11516000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	15787000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15411000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5142000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5824000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	44579000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	54354000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17140000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17259000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14419000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15174000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7452000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7452000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1609000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1618000	usd
CY2022Q4	us-gaap	Assets Assets	85199000	usd
CY2022Q3	us-gaap	Assets Assets	95857000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	8109000	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	8508000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12377000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3455000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3432000	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	312000	usd
CY2022Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	310000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24253000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24550000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11952000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12729000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3986000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4077000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	40209000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	41395000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48720454	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48720454	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48720454	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48720454	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	487000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	487000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	339892000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	339462000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299273000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288638000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3884000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3151000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44990000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	54462000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85199000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95857000	usd
CY2022Q4	us-gaap	Revenues Revenues	18276000	usd
CY2021Q4	us-gaap	Revenues Revenues	26519000	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	14671000	usd
CY2021Q4	us-gaap	Cost Of Revenue CostOfRevenue	15273000	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	996000	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	744000	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11451000	usd
CY2021Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11052000	usd
CY2022Q4	us-gaap	Legal Fees LegalFees	1071000	usd
CY2021Q4	us-gaap	Legal Fees LegalFees	1282000	usd
CY2022Q4	enz	Total Costs Expenses And Legal Settlements Net TotalCostsExpensesAndLegalSettlementsNet	28189000	usd
CY2021Q4	enz	Total Costs Expenses And Legal Settlements Net TotalCostsExpensesAndLegalSettlementsNet	28351000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9913000	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1832000	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000	usd
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	usd
CY2021Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-145000	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-797000	usd
CY2021Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-381000	usd
CY2022Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-722000	usd
CY2021Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-487000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10635000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48720	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48472	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48720	shares
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48472	shares
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10635000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	733000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	277000	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9902000	usd
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2042000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	54462000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10635000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	430000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	733000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44990000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	68586000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	216000	usd
CY2021Q4	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-3724000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	277000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	66760000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10635000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	780000	usd
CY2021Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	611000	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22000	usd
CY2021Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	90000	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	430000	usd
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	216000	usd
CY2022Q4	enz	Sharebased401k Employer Match Expense Sharebased401kEmployerMatchExpense	198000	usd
CY2021Q4	enz	Sharebased401k Employer Match Expense Sharebased401kEmployerMatchExpense	167000	usd
CY2022Q4	enz	Foreign Currency Gain Loss On Intercompany Loan ForeignCurrencyGainLossOnIntercompanyLoan	-783000	usd
CY2021Q4	enz	Foreign Currency Gain Loss On Intercompany Loan ForeignCurrencyGainLossOnIntercompanyLoan	-342000	usd
CY2021Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-196000	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1120000	usd
CY2022Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	393000	usd
CY2021Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1289000	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-666000	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-171000	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-407000	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2198000	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-126000	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-910000	usd
CY2022Q4	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1942000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8693000	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6043000	usd
CY2021Q4	enz	Salespurchases Of Marketable Securities SalespurchasesOfMarketableSecurities	28000	usd
CY2022Q4	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	652000	usd
CY2021Q4	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1033000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-652000	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1061000	usd
CY2022Q4	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	95000	usd
CY2021Q4	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	57000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-95000	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57000	usd
CY2022Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-28000	usd
CY2021Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9468000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7168000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22603000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14274000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13135000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7106000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12135000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6356000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	usd
CY2022Q4	enz	Cash Cash Equivalentsand Restricted Cash CashCashEquivalentsandRestrictedCash	13135000	usd
CY2021Q4	enz	Cash Cash Equivalentsand Restricted Cash CashCashEquivalentsandRestrictedCash	7106000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	9000	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	5000	usd
CY2022Q4	enz	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	1000	usd
CY2021Q4	enz	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	11000	usd
CY2022Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	210000	usd
CY2022Q4	enz	Finance Leases Liability FinanceLeasesLiability	99000	usd
CY2022Q4	us-gaap	Net Income Loss Allocated To General Partners NetIncomeLossAllocatedToGeneralPartners	10635000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	8693000	usd
CY2022Q3	enz	Service Revenue Percentage ServiceRevenuePercentage	0.44	pure
CY2022Q4	enz	Service Revenue Percentage ServiceRevenuePercentage	0.07	pure
CY2022Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p>
CY2022Q4	enz	Clinical Services Net Revenue ClinicalServicesNetRevenue	0.15	pure
CY2022Q4	enz	Services Net Accounts Receivable Percentage ServicesNetAccountsReceivablePercentage	0.16	pure
CY2022Q4	enz	Clinical Services Net Accounts Receivable ClinicalServicesNetAccountsReceivable	0.36	pure
CY2022Q4	enz	Finance Leases Liability Noncurrent FinanceLeasesLiabilityNoncurrent	18000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	106000
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	541000
CY2022Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2595000	shares
CY2021Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	793000	shares
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	53000	usd
CY2021Q4	us-gaap	Interest Paid Net InterestPaidNet	56000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1958000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1524000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2644000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2459000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11185000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11428000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	15787000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15411000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	7452000	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	7452000	usd
CY2018Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4500000	usd
CY2018Q4	enz	Debt Instrument Maturity Period DebtInstrumentMaturityPeriod	10 years
CY2018Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0509	pure
CY2018Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	30000	usd
CY2018Q4	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	72000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	44000	usd
CY2022Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	3941000	usd
CY2022Q4	us-gaap	Cash Collateral For Borrowed Securities CashCollateralForBorrowedSecurities	1000000	usd
CY2022Q4	enz	Liquid Assets LiquidAssets	25000000	usd
CY2021Q3	enz	Description Of Loan DescriptionOfLoan	Effective September 29, 2021, the Company and the mortgagee agreed to further covenant restructuring whereby (a) the liquidity covenant was reduced to 150% of the loan principal (or approximately $5,911 as of October 31, 2022) from $25,000 previously, and (b) the collateral requirement was increased from $750 to $1,000.
CY2020Q2	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	chf
CY2020Q2	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	usd
CY2022Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0	pure
CY2022Q1	enz	Semiannual Amortization Payments SemiannualAmortizationPayments	33000	chf
CY2022Q3	enz	Exchange Rates ExchangeRates	33000	chf
CY2022Q3	enz	Exchange Rates ExchangeRates	35000	usd
CY2021	enz	Other Income Loan OtherIncomeLoan	7000000	usd
CY2022Q4	enz	Audit Loans AuditLoans	2000000	usd
CY2021Q3	enz	Finance Leases Liability Noncurrent FinanceLeasesLiabilityNoncurrent	39000	usd
CY2022Q4	enz	Lease Liability LeaseLiability	15506000	usd
CY2021Q3	enz	Lease Liability LeaseLiability	16281000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	228000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	154000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	234000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	244000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	253000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	263000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3110000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	4258000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	228000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	44000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	3986000	usd
CY2022Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P12M
CY2022Q4	enz	Lease Option Maximum Extension Period LeaseOptionMaximumExtensionPeriod	P5Y
CY2022Q4	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	408000	usd
CY2021Q4	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	212000	usd
CY2022Q4	enz	Operating Rightofuse Assets OperatingRightofuseAssets	14419000	usd
CY2021Q3	enz	Operating Rightofuse Assets OperatingRightofuseAssets	15174000	usd
CY2022Q4	enz	Lease Rightof Use Asset LeaseRightofUseAsset	14572000	usd
CY2021Q3	enz	Lease Rightof Use Asset LeaseRightofUseAsset	15346000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3455000	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3432000	usd
CY2022Q4	enz	Finance Leases Liability Current FinanceLeasesLiabilityCurrent	81000	usd
CY2021Q3	enz	Finance Leases Liability Current FinanceLeasesLiabilityCurrent	81000	usd
CY2022Q4	enz	Operating Operating Lease Liabilities Noncurrent OperatingOperatingLeaseLiabilitiesNoncurrent	11952000	usd
CY2021Q3	enz	Operating Operating Lease Liabilities Noncurrent OperatingOperatingLeaseLiabilitiesNoncurrent	12729000	usd
CY2022Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	1048000	usd
CY2021Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	1158000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000	usd
CY2022Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2021Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2022Q4	us-gaap	Lease Cost LeaseCost	1069000	usd
CY2021Q4	us-gaap	Lease Cost LeaseCost	1180000	usd
CY2022Q4	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	22000	usd
CY2021Q4	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	4000	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	430000	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	216000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3118000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	3184000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3874000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	37000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	3911000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3541000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	3541000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3351000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	3351000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2507000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2507000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	808000	usd
CY2022Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	808000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17199000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	103000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	17302000	usd
CY2022Q4	enz	Present Value Of Lease Liabilities Operating Leases PresentValueOfLeaseLiabilitiesOperatingLeases	15407000	usd
CY2022Q4	enz	Contractual Obligation Liability ContractualObligationLiability	15506000	usd
CY2022Q4	enz	Lease Term And Discount Rate LeaseTermAndDiscountRate	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Lease term and discount rate</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Weighted-average remaining lease term (years):</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-size: 10pt">4.5 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">5.4 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-size: 10pt">1.2 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">2.0 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0.125in">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.95</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.72</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0495	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.037	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0672	pure
CY2022Q4	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2600000	usd
CY2022Q4	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	2123000	usd
CY2022Q3	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	1024000	usd
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	583-0100
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4616000	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4912000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	788000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	801000	usd
CY2022Q4	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	4616000	usd
CY2022Q3	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	4523000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2357000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2064000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12377000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	235000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	260000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	enz	Percentage Of Commission Payable On Equity Offering PercentageOfCommissionPayableOnEquityOffering	0.03	pure
CY2020Q4	enz	Common Stock Available For Grant Description CommonStockAvailableForGrantDescription	The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030.
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4357000	shares
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	244000	usd
CY2021Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	216000	usd
CY2022Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	186000	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	430000	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	216000	usd
CY2022Q4	dei	City Area Code CityAreaCode	212
CY2022Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q4	enz	Salespurchases Of Marketable Securities SalespurchasesOfMarketableSecurities		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3941783	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.42
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	251066	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3705717	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	1794399	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y7M6D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1997	usd
CY2022Q4	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P2Y
CY2022Q4	enz	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredRemainingContractualTerm1	P3Y
CY2022Q4	enz	Performance Shares Description PerformanceSharesDescription	During the fiscal years ended 2020 and 2019, the Company awarded additional PSUs to its executive officers. These awards provide for the grant of shares of our common stock at the end of a three-year period based on the achievement of revenue growth and adjusted EBITDA growth goals met at threshold, target or maximum levels over the respective period. The PSUs awarded to executive officers in fiscal 2019, net of forfeitures, were earned as of the three-year period ending July 31, 2022 as the growth goals at the maximum level were achieved. After TSR modification, a total of 25,200 PSUs were earned equally by two officers. The shares will be issued in the second quarter of fiscal 2023. During the three months ended October 31, 2022 a former officer forfeited 15,000 PSUs awarded in fiscal 2020, and the Company reversed PSU accruals of $55 related to the fiscal 2020 awards. During the three months ended October 31, 2021 the Company accrued PSU compensation expense of $66.
CY2022Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	186000	usd
CY2021Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022Q4	enz	Unrecognized Compensation UnrecognizedCompensation	1295000	usd
CY2022Q4	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 12 – Contingencies</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ’180 and ’405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ’180 and ’405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, along with its subsidiary Enzo Life Sciences, Inc., resolved its claims against Roche regarding the ‘197 Patent before the Court (civil action No. 12 cv-00106) in July 2022. There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ‘197 patent against Becton Dickinson Defendants. The claims in that case are stayed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In separate inter partes review proceedings before the U.S. Patent and Trademark Office (PTO) involving, among others, Becton Dickinson, certain claims of the ’197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which was denied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ’180 and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the <i>inter partes</i> review proceedings regarding the ’197 Patent filed by Hologic and joined by Becton Dickinson mentioned above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 2, 2021, the PTO issued a non-final office action in an <i>ex parte</i> reexamination concerning the ’197 Patent. In the office action, the PTO rejected certain claims of the ’197 Patent under 35 U.S.C. §§ 102 and 103, and for nonstatutory double-patenting. Enzo responded to the office action on January 3, 2022, and the proceeding remains pending. Becton Dickinson requested another <i>ex parte</i> reexamination concerning the ’197 patent on July 26, 2022. On September 16, 2022, the PTO ordered that <i>ex parte </i>reexamination as to certain claims of the ’197 patent and has not yet issued an office action. Enzo filed a petition to terminate that second reexamination proceeding on November 16, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“HDF”) brought an action in the United States District Court for the Southern District of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer. On March 26, 2020, HDF filed an amended complaint against the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made purportedly false statements. Count II asserted a claim against the individual defendants under Section 20(a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Finally, Count IV purported to assert a derivative claim for a declaration that any amendment to Article II, Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the day before the defendants’ motion to dismiss was due, HDF asked the Court to dismiss their claims without prejudice. Defendants asked HDF to dismiss the claims with prejudice, but they refused. On July 17, 2020, the Court dismissed the claims without prejudice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 27, 2020, the Company brought an action in the United States District Court for the Southern District of New York against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp. and Kenan Lucas (together, “Harbert”). The Company alleges Harbert made false and misleading representations, or omitted to state material facts necessary to make their statements not misleading, in proxy materials they disseminated seeking the election to the Company’s Board of Directors at its 2019 Annual Meeting of two candidates they nominated, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder. The Company seeks damages and injunctive relief. On October 12, 2021, HDF filed nine counterclaims against the Company and present and former directors Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky, Rebeca Fischer, Dr. Mary Tagliaferri and Dr. Ian B. Walters. HDF claims the Company made false and misleading representations in proxy materials it disseminated in connection with its 2019 Annual Meeting, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder, and that the Company’s directors at that time are liable under Section 20(a) of the Exchange Act for the Company’s purported misstatements. HDF also claims that current and former Company directors breached their fiduciary duties by taking four corporate actions: (a) adjourning the 2019 meeting for 25 days; (b) purportedly causing the two Harbert candidates for director, who were elected at the 2019 Meeting, to resign in November 2020; (c) authorizing the November 27, 2020 Lawsuit; and (d) not accepting Dr. Rabbani’s resignation as a director in March 2021. On November 10, 2021, the Company and the other counterclaim defendants moved to dismiss HDF’s counterclaims. On December 9, 2021, the court granted the motion to dismiss HDF’s counterclaims except HDF’s Section 14(a) claim against the Company concerning its statement that it intended to “delay” the 2019 Annual Meeting, and HDF’s Section 20(a) and breach of fiduciary duty counterclaims against Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce Hanna, Dov Perlysky and Rebecca Fischer with respect to that statement. The Court allowed HDF to move for leave to replead with respect to its dismissed counterclaims. On June 7, 2022, the Court “so ordered” a stipulation of dismissal with prejudice of the Company’s claims against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp., and Kenan Lucas, and HDF’s counterclaims against the Company, Dr. Bruce Hanna, Dov Perlysky, Rebecca Fischer, Dr. Ian B. Walters and Dr. Mary Tagliaferri. The only remaining claims were HDF’s counterclaims against Dr. Rabbani and Mr. Weiner. HDF asked the Court to dismiss those claims without prejudice. Dr. Rabbani and Mr. Weiner asked the Court to dismiss those counterclaims with prejudice and to allow them to take discovery from HDF, the Company, and possibly others. On December 1, 2022, the court granted HDF’s motion for voluntary dismissal without prejudice, denied Dr. Rabbani and Mr. Weiner’s motion to compel discovery, and directed the Clerk of the Court to close this case.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Former executives arbitration</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company terminated the employment of Elazar Rabbani, Ph.D. the Company’s former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani remains a board director of the Company. Dr. Rabbani is a party to an employment agreement with the Company, which entitles him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, and continuation of benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of $2,600 in fiscal 2022 which is included in Selling, general and administrative expenses. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani $2,123 in severance (the payment constituted taxable income but the Company did not withhold taxes from the payment). In July 2022, the Company paid Dr. Rabbani’s income and other withholding taxes of $1,024 related to that payment on Dr. Rabbani’s behalf, which is included in “prepaid expense and other current assets” as of July 31, 2022, as the payment is reimbursable from Dr. Rabbani. Dr. Rabbani disputed, among other things, the Company’s decision to not award him a bonus for fiscal year 2021 and the amount of severance that was owed to him under his employment agreement. On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the “AAA”) seeking, among other things, a declaration that the Company has fully satisfied its contractual obligations to Dr. Rabbani and seeking the tax withholding reimbursement referenced above. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserts is owed to him. The parties have chosen an arbitrator from the AAA’s panel and a hearing is scheduled for June 8-16, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 25, 2022, Barry Weiner, the Company’s co-founder and President, notified the Company that he was terminating his employment as President of the Company for “Good Reason” as defined in his employment agreement. The Company accepted Mr. Weiner’s termination, effective April 19, 2022 but disagreed with Mr. Weiner’s assertion regarding “Good Reason.” On July 20, 2022, Mr. Weiner filed a demand for arbitration with the AAA asserting, among other things, that his annual bonus for fiscal year 2021 was too low and that his resignation (effective April 19, 2022) was for “Good Reason” under the terms of his employment agreement. He seeks, among other things, payment of a higher 2021 bonus, and severance payments and benefits. The parties have chosen an arbitrator from the AAA’s panel and a hearing is scheduled for July 18-21, and 24, 2023. As of October 31, 2022, the Company has not accrued any charges related to Mr. Weiner’s termination.</p>
CY2022Q4	enz	Approval Percentage ApprovalPercentage	0.80	pure
CY2021Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0000316253

Files In Submission

Name	View Source	Status
0001213900-22-079139-index-headers.html	Edgar Link	pending
0001213900-22-079139-index.html	Edgar Link	pending
0001213900-22-079139.txt	Edgar Link	pending
0001213900-22-079139-xbrl.zip	Edgar Link	pending
enz-20221031.xsd	Edgar Link	pending
f10q1022ex31-1_enzobio.htm	Edgar Link	pending
f10q1022ex31-2_enzobio.htm	Edgar Link	pending
f10q1022ex32-1_enzobio.htm	Edgar Link	pending
f10q1022ex32-2_enzobio.htm	Edgar Link	pending
f10q1022_enzobio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
enz-20221031_def.xml	Edgar Link	unprocessable
enz-20221031_pre.xml	Edgar Link	unprocessable
enz-20221031_lab.xml	Edgar Link	unprocessable
enz-20221031_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q1022_enzobio_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENZ
ENZO BIOCHEM INC Stock $enz

2022 Q4 Form 10-Q Financial Statement

#000121390022079139 Filed on December 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ ENZO BIOCHEM INC Stock $enz

2022 Q4 Form 10-Q Financial Statement

#000121390022079139 Filed on December 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ
ENZO BIOCHEM INC Stock $enz